Research ArticleDrug Discovery and Translational Medicine
Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3–Related Dwarfism
Daniel J. Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M. Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A. O’Neill, Pavel Krejci, William R. Wilcox, David L. Rimoin and Stuart Bunting
Journal of Pharmacology and Experimental Therapeutics April 2015, 353 (1) 132-149; DOI: https://doi.org/10.1124/jpet.114.218560
Daniel J. Wendt
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Melita Dvorak-Ewell
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Sherry Bullens
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Florence Lorget
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Sean M. Bell
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Jeff Peng
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Sianna Castillo
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Mika Aoyagi-Scharber
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Charles A. O’Neill
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Pavel Krejci
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
William R. Wilcox
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
David L. Rimoin
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
Stuart Bunting
BioMarin Pharmaceutical Inc., Novato, California (D.J.W., M.D.-E., Sh.B., F.L., S.M.B., J.P., S.C., M.A.-S., C.A.O., St.B.); and Cedars-Sinai Medical Center, Los Angeles, California (P.K., W.R.W., D.L.R.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
C-Type Natriuretic Peptide Variant for FGFR3-Related Dwarfism
Daniel J. Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M. Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A. O’Neill, Pavel Krejci, William R. Wilcox, David L. Rimoin and Stuart Bunting
Journal of Pharmacology and Experimental Therapeutics April 1, 2015, 353 (1) 132-149; DOI: https://doi.org/10.1124/jpet.114.218560
Research ArticleDrug Discovery and Translational Medicine
C-Type Natriuretic Peptide Variant for FGFR3-Related Dwarfism
Daniel J. Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M. Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A. O’Neill, Pavel Krejci, William R. Wilcox, David L. Rimoin and Stuart Bunting
Journal of Pharmacology and Experimental Therapeutics April 1, 2015, 353 (1) 132-149; DOI: https://doi.org/10.1124/jpet.114.218560
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement